{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:35:18Z","timestamp":1775208918661,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Sanofi-Aventis, Czech Republic","award":["DIREGL07340"],"award-info":[{"award-number":["DIREGL07340"]}]},{"name":"Sanofi-Aventis, Czech Republic"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.atherosclerosis.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T09:46:59Z","timestamp":1538128019000},"page":"355-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-1926","authenticated-orcid":false,"given":"Michal","family":"Vrablik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-0906","authenticated-orcid":false,"given":"Katarina","family":"Raslov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Vohnout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Satny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Kyselak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Vaclova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Maskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Soska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-7053","authenticated-orcid":false,"given":"Tomas","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib1","first-page":"99","article-title":"Preventing early cardiovascular death in patients with familial hypercholesterolemia","volume":"114","author":"Repas","year":"2014","journal-title":"J. Am. Osteopath. Assoc."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2018.08.008_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib3","series-title":"Human Genetics Programme","author":"World Health Organization (WHO)","year":"1998"},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5 - year SAFEHEART Registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib6","unstructured":"http:\/\/www.medped.org (Accessed 23 May 2017)."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.008_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(03)00023-0","article-title":"Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B-100: the MEDPED Slovakia Project","volume":"4","author":"Vohnout","year":"2003","journal-title":"Atheroscler Suppl. Nov"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.008_bib8","first-page":"e95","article-title":"Slovak MED PED FH group. Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity?","volume":"194","author":"Gasparovic","year":"2007","journal-title":"Atherosclerosis"},{"issue":"Supplementum 1","key":"10.1016\/j.atherosclerosis.2018.08.008_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33549\/physiolres.933600","article-title":"Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project","volume":"66","author":"Vrabl\u00edk","year":"2017","journal-title":"Physiol. Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.008_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.008_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pds.1471","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"17","author":"International Society for Pharmacoepidemiology","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib12","series-title":"Good Epidemiological Practice: IEA Guidelines for Proper Conduct of Epidemiological Research","author":"International Epidemiological Association (IEA)","year":"2007"},{"issue":"25 Pt B","key":"10.1016\/j.atherosclerosis.2018.08.008_bib13","first-page":"2889","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib14","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacl.2007.07.003","article-title":"Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia","volume":"1","author":"Stein","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1177\/2047487316667784","volume":"18","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.008_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00109-005-0019-z","article-title":"Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing","volume":"84","author":"Humphries","year":"2006","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2018.08.008_bib19","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2016","key":"10.1016\/j.atherosclerosis.2018.08.008_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib21","article-title":"Alirocumab cuts CV events, all-cause death post-ACS","volume":"10","author":"ODYSSEY Outcomes","year":"2018","journal-title":"Medscape - Mar"},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6807","key":"10.1016\/j.atherosclerosis.2018.08.008_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","author":"Scientific Steering Committee on behalf of the Simon Broome Register Group","year":"1991","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2018.08.008_bib24","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-511X-10-94","article-title":"Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish familial hypercholesterolemia Longitudinal cohort study (SAFEHEART)","volume":"10","author":"Mata","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.008_bib26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacl.2017.12.014","article-title":"Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy","volume":"12","author":"Galema-Boers","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2018.08.008_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.amjcard.2017.12.040","article-title":"Efficacy and safety of alirocumab in high-risk patients with clinical atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from 5 placebo-controlled ODYSSEY trials)","volume":"121","author":"McCullough","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.08.008_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2017.10.006","article-title":"Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH\u2122 patient registry","volume":"267","author":"Amrock","year":"2017","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.08.008_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.recesp.2016.10.012","article-title":"Attainment of LDL cholesterol treatment goals in children and adolescents with familial hypercholesterolemia. The SAFEHEART follow-up registry","volume":"70","author":"Saltijeral","year":"2017","journal-title":"Rev Esp Cardiol. (Engl Ed). Jun"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018312577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018312577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:23:37Z","timestamp":1762187017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018312577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"alternative-id":["S0021915018312577"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.008","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}